Trials / Completed
CompletedNCT03846453
A Study to Assess Efficacy and Safety of HL036 in Subjects With Dry Eyes
A Phase 3, Multicenter, Randomized, Double-Masked and Placebo-Controlled Study Evaluating the Efficacy and Safety of 0.25% HL036 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 637 (actual)
- Sponsor
- HanAll BioPharma Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study was to compare the safety and efficacy of 0.25% HL036 Ophthalmic Solutions to placebo for the treatment of the signs and symptoms of dry eye.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | HL036 Ophthalmic Solution | HL036 Ophthalmic Solution |
| BIOLOGICAL | Placebo | Placebo vehicle solution |
Timeline
- Start date
- 2019-03-10
- Primary completion
- 2019-11-22
- Completion
- 2019-11-22
- First posted
- 2019-02-19
- Last updated
- 2022-04-14
- Results posted
- 2022-04-14
Locations
12 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03846453. Inclusion in this directory is not an endorsement.